BofA/Merrill Lynch Upgrades Acadia Pharmaceuticals (ACAD) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results
November 7, 2016 4:05 PM ESTNUPLAZID® Net Product Sales Grew to $5.3 Million in the First Full Quarter of Commercialization
Expanding Pimavanserin Clinical Program With Initiation of Studies for Alzheimers Disease Agitation and Adjunctive Treatment of Schizophrenia
SAN DIEGO--(BUSINESS WIRE)-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its unaudited financial results for the third quarter ended September 30, 2016.
We are very pleased with the launch... More
